+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Respiratory Partnering 2010-2022: Deal Trends, Players and Financials

  • PDF Icon


  • 650 Pages
  • November 2022
  • Region: Global
  • CurrentPartnering
  • ID: 2229065
Global Respiratory Partnering 2010 to 2022 provides the full collection of Respiratory disease deals signed between the world’s pharmaceutical and biotechnology companies since 2010.
  • Trends in Respiratory partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Respiratory partnering agreement structure
  • Respiratory partnering contract documents
  • Top Respiratory deals by value
  • Most active Respiratory dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Respiratory disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Respiratory deals.

The report presents financial deal terms values for Respiratory deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Respiratory dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Respiratory dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Respiratory deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Respiratory dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Respiratory deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Respiratory partnering deals by specific Respiratory target announced since 2010. The chapter is organized by specific Respiratory therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Respiratory partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Respiratory partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Respiratory technologies and products.

Report scope

Global Respiratory Partnering 2010 to 2022 is intended to provide the reader with an in-depth understanding and access to Respiratory trends and structure of deals entered into by leading companies worldwide.

Global Respiratory Partnering 2010 to 2022 includes:

  • Trends in Respiratory dealmaking in the biopharma industry since 2010
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Respiratory deal contract documents
  • Comprehensive access to over 1000 Respiratory deal records
  • The leading Respiratory deals by value since 2010
  • Most active Respiratory dealmakers since 2010
The report includes deals for the following indications: Allergic rhinitis, Acute respiratory distress syndrome, Asthma, Bronchitis, Chronic obstructive pulmonary disease, Emphysema, Idiopathic pulmonary fibrosis, Occupational Lung Disease, Asbestosis, Coalworkers pneumoconiosis, Hypersensitivity pneumonitis, Silicosis, Pneumonia, Pulmonary arterial hypertension, Pulmonary embolism, Respiratory Tract Infection, Sarcoidosis, Sinusitis, Breathlessness, Bronchospasm, Chest Pain, Cough, Nasal congestation, Snoring, Wheeze, plus other respiratory indications.

In Global Respiratory Partnering 2010 to 2022, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Respiratory Partnering 2010 to 2022 report provides comprehensive access to available deals and contract documents for over 1000 respiratory deals.

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive SummaryChapter 1 - Introduction
Chapter 2 - Trends in Respiratory dealmaking
2.1. Introduction
2.2. Respiratory partnering over the years
2.3. Respiratory partnering by deal type
2.4. Respiratory partnering by industry sector
2.5. Respiratory partnering by stage of development
2.6. Respiratory partnering by technology type
2.7. Respiratory partnering by therapeutic indication
Chapter 3 -Financial deal terms for Respiratory partnering
3.1. Introduction
3.2. Disclosed financials terms for Respiratory partnering
3.3. Respiratory partnering headline values
3.4. Respiratory deal upfront payments
3.5. Respiratory deal milestone payments
3.6. Respiratory royalty rates
Chapter 4 - Leading Respiratory deals and dealmakers
4.1. Introduction
4.2. Most active in Respiratory partnering
4.3. List of most active dealmakers in Respiratory
4.4. Top Respiratory deals by value
Chapter 5 - Respiratory contract document directory
5.1. Introduction
5.2. Respiratory partnering deals where contract document available
Chapter 6 - Respiratory dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Respiratory therapeutic target
Appendix 1 - Directory of Respiratory deals by company A-Z 2010 to 2022
Appendix 2 - Directory of Respiratory deals by deal type 2010 to 2022
Appendix 3 - Directory of Respiratory deals by stage of development 2010 to 2022
Appendix 4 - Directory of Respiratory deals by technology type 2010 to 2022
Further reading on dealmaking
Deal type definitions
Table of figures
Figure 1: Respiratory partnering since 2010
Figure 2: Respiratory partnering by deal type since 2010
Figure 3: Respiratory partnering by industry sector since 2010
Figure 4: Respiratory partnering by stage of development since 2010
Figure 5: Respiratory partnering by technology type since 2010
Figure 6: Respiratory partnering by indication since 2010
Figure 7: Respiratory deals with a headline value
Figure 8: Respiratory deals with upfront payment values
Figure 9: Respiratory deals with milestone payment
Figure 10: Respiratory deals with royalty rates
Figure 11: Active Respiratory dealmaking activity- 2010 to 2022
Figure 12: Top Respiratory deals by value since 2010

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Alnylam Pharmaceuticals
  • Vortran Medical
  • Sichuan University
  • Lung and Blood Institute
  • Food and Drug Administration (FDA)
  • Bill and Melinda Gates Foundation
  • Zhejiang Medicine
  • Jubilant DraxImage
  • Enzyvant Science
  • Altavant Sciences
  • Biostar Pharmaceuticals
  • Scholar Rock
  • Monopar Therapeutics
  • Wockhardt
  • Innovare
  • Celularity
  • Highmark Blue Shield
  • Highmark Health
  • Glenmark Pharmaceuticals
  • 4D Pharma
  • BESPharma
  • IR Pharma
  • SI Pharmaceuticals
  • Wal-Mart
  • Sanovas
  • Amyndas Pharmaceuticals
  • Tunitas Therapeutics
  • Innovata HK
  • Medidata Solutions
  • Advocate Health Care
  • Innovate UK
  • Foundation for Sarcoidosis Research
  • Simulations Plus
  • Innovative Genomics Initiative (IGI)
  • Innovative Medicines Initiative (IMI)
  • Laboratory Corporation of America
  • Novavax
  • Dynavax Technologies
  • Pharmaxis
  • Scarab Genomics
  • Punjab Province


  • The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
  • The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
  • The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
  • The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
  • The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

The publisher provides comprehensive coverage of the following partnering or deal types:

  • Asset purchase
  • Assignment
  • Co-development
  • Co-market
  • Co-promotion
  • Collaborative R&D
  • Contract service
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Loan
  • Manufacturing
  • Marketing
  • Option
  • Promotion
  • Research
  • Royalty financing
  • Settlement
  • Spin out
  • Sub license
  • Supply
  • Termination
  • Warrant

Every deal record is fully categorized and includes the following data, where available:

  • Industry sector
  • Therapy areas
  • Technology type
  • Deal components
  • Financial terms
  • Stage of development
  • Exclusivity
  • Asset type
  • Geographic focus
  • Excluded geography
  • Company press release
  • SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.